Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:57:23.870Z.
Calculation as of: 2026-10-06T16:57:23.870Z.
Quote observation: 2026-10-06T16:55:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 757805bafeebc6dd018a704dcae2ac70006cc574d7bdbc7e38b059e75a8ad8a2
PE RATIO
N/A
Lumexa Imaging Holdings, Inc. Common Stock
Market Cap
$1.03B
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.04B
PE Ratio
N/A
TTM Avg
50.11
3Y Avg
34.45
5Y Avg
50.26
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI) | $1.03B | N/A | N/A | N/A | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.03B | N/A | 100.60 | 100.60 | 255.09 |
| Immatics N.V. (IMTX)vs › | $1.03B | N/A | 31.31 | 24.04 | 24.04 |
| Janux Therapeutics, Inc. (JANX)vs › | $1.03B | N/A | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.04B | N/A | 5.99 | 5.99 | 5.99 |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.04B | N/A | 50.11 | 34.45 | 50.26 |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $1.00B | N/A | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | N/A | N/A | N/A | N/A |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $991.81M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $982.98M | 71.14 | 118.14 | 119.36 | 99.91 |
Trailing P/E
N/A
Forward P/E
16.6
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$10.68
Forward EPS (Est.)
$0.64
Forward P/E
16.64
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
